Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review

Alexander Weymann; Sadeq Ali-Hasan-Al-Saegh; Anton Sabashnikov; Aron-Frederik Popov; Seyed Jalil Mirhosseini; Luis Nombela-Franco; Luca Testa; Mohammadreza Lotfaliani; Mohamed Zeriouh; Tong Liu; Hamidreza Dehghan; Senol Yavuz; Michel Pompeu Barros de Oliveira Sá; William L. Baker; Jae-Sik Jang; Mengqi Gong; Umberto Benedetto; Pascal M. Dohmen; Fabrizio D'Ascenzo; Abhishek J. Deshmukh; Giuseppe Biondi-Zoccai; Hugh Calkins; Gregg W. Stone; Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group [IMCSC-Group]

doi:10.12659/MSMBR.902557

17 March 2017 : Meta-Analysis

Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review

Alexander Weymann^{ABCDEFG 1*}, Sadeq Ali-Hasan-Al-Saegh^{ABCDEFG 2}, Anton Sabashnikov^{ABCDEFG 3,4}, Aron-Frederik Popov^{ABCDEFG 5}, Seyed Jalil Mirhosseini^{ABCDEFG 2}, Luis Nombela-Franco^{ABCDEFG 6}, Luca Testa^{ABCDEFG 7}, Mohammadreza Lotfaliani^{ABCDEFG 2}, Mohamed Zeriouh^{ABCDEFG 3,4}, Tong Liu^{ABCDEFG 8}, Hamidreza Dehghan^{ABCDEFG 9}, Senol Yavuz^{ABCDEFG 10}, Michel Pompeu Barros de Oliveira Sá^{ABCDEFG 11,12,13}, William L. Baker^{ABCDEFG 14}, Jae-Sik Jang^{ABCDEFG 15}, Mengqi Gong^{ABCDEFG 8}, Umberto Benedetto^{ABCDEFG 16}, Pascal M. Dohmen^{DFG 1}, Fabrizio D'Ascenzo^{ABCDEFG 17}, Abhishek J. Deshmukh^{ABCDEFG 18}, Giuseppe Biondi-Zoccai^{ABCDEFG 19,20}, Hugh Calkins^{DE 21}, Gregg W. Stone^{DE 22}, Integrated Meta-Analysis of Cardiac Surgery and Cardiology-Group [IMCSC-Group]

DOI: 10.12659/MSMBR.902557

Med Sci Monit Basic Res 2017; 23:58-86

Authors information Article notes Copyright and License information

¹Department of Cardiac Surgery, University Hospital Oldenburg, European Medical School Oldenburg-Groningen, Carl von Ossietzky University Oldenburg, Oldenburg, Germany
²Cardiovascular Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
³Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, Harefield Hospital, Harefield Middlesex, United Kingdom
⁴Department of Cardiothoracic Surgery, University Hospital Cologne, Cologne, Germany
⁵Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom
⁶Instituto Cardiovascular, Hospital Universitario Clínico San Carlos, Madrid, Spain
⁷Department of Cardiology, IRCCS Pol. S. Donato, S. Donato Milanese, Milan, Italy
⁸Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, China
⁹Department of Health Technology Assessment, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran
¹⁰Department of Cardiovascular Surgery, Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Turkey
¹¹ University of Pernambuco – UPE, Recife, Brazil
¹² Nucleus of Postgraduate and Research in Health Sciences of Faculty of Medical Sciences and Biological Sciences Institute (FCM/ICB), Recife, Brazil
¹³ Division of Cardiovascular Surgery of Pronto Socorro Cardiológico de Pernambuco – PROCAPE, Recife, Brazil
¹⁴ University of Connecticut/Hartford Hospital Evidence-Based Practice Center, Hartford, USA
¹⁵Department of Cardiology, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
¹⁶Bristol Heart Institute, University of Bristol, School of Clinical Sciences, Bristol, United Kingdom
¹⁷Division of Cardiology, Department of Medical Sciences, Città della Salute e della Scienza Hospital, University of Turin, Turin, Italy
¹⁸Mayo Clinic Heart Rhythm Section, Cardiovascular Diseases, Mayo Clinic, Rochester, USA
¹⁹Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy
²⁰Department of AngioCardioNeurology, IRCCS Neuromed, Pozzilli, Italy
²¹Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, USA
²²New York Presbyterian Hospital, Columbia University Medical Center, New York, USA

^*Corresponding Author: Alexander Weymann, e-mail: [email protected]

^AStudy design/planning
^BData collection/entry
^CData analysis/statistics
^DData interpretation
^EPreparation of manuscript
^FLiterature analysis/search
^GFunds collection

Related articles Order reprints Share article Share by email

View HTML version

Supplementary Table 2. Extra details of characteristics of each study for exploration of heterogeneity factors.

First Author	Geographic Area	Total N	Total age	Total male	Total DM	Total HTN	Total MI	Total Diuretic	Total ACEI	Total. Statin	Total BB	AC-code	Chronic or not	CS
Karatas []²⁰	European	621	61.05	72.5	23	45.5	ND	ND	ND	0	ND	2	Non-chronic	64
Drabik []²¹	European	97	60.1	64.95	20	48.85	17.3	ND	52.25	53.15	60.6	4	Non-chronic	22.85
Drabik []²¹	European	91	60	55.15	16.4	46.05	26.2	ND	54.05	47.45	57.25	4	Non-chronic	20
Idriss []²²	Africa	41	31.75	49.25	0	0	ND	ND	ND	ND	11.9	4	ND	34.5
Akdag []²³	European	148	64.05	60	16.5	22	ND	ND	ND	ND	ND	6	ND	23.5
Akyuz []²⁴	European	90	62.25	72.25	29	42.5	ND	14.5	20.75	32.5	23	4	ND	34.25
Chavaria []²⁵	North American	290	65.65	74.5	29.05	65.65	4.5	ND	ND	ND	ND	5	ND	55.05
Erdogan []²⁶	European	67	69.55	49.25	10	65	ND	18	53.5	10	43.3	3	chronic	6
Xu (without comorbidities) []²⁷	Asian	115	66.05	50.45	37.4	53.1	ND	ND	42.6	29.55	43.55	4	chronic	38.25
Xu (with comorbidities) []²⁷	Asian	115	67.975	51.3	36.5	57.5	ND	ND	40.8	26.05	40.95	4	chronic	31.25
Acet (PAF) []²⁸	European	134	62.05	44	16.5	18	ND	ND	ND	ND	ND	5	Non-chronic	21.5
Acet (persistent and permanent) []²⁸	European	126	62.85	43.5	21.5	24	ND	ND	ND	ND	ND	5	ND	28.5
Arik (with INR 2–3) []²⁹	European	248	69.65	40.7	6.05	68.95	ND	27	59.25	ND	59.7	5	chronic	13.7
Arik (with abnormal INR) []²⁹	European	248	69.45	37.9	6.85	65.35	ND	24.2	55.65	ND	61.3	5	chronic	12.1
Distelmaier []³⁰	North American	198	73.5	61	24	60.5	25	ND	ND	ND	ND	5	Non-chronic	ND
Gungor []³¹	European	177	47.2	57.8	3.3	14.75	ND	ND	ND	ND	10.6	3	ND	23.15
Sonmez []³²	European	85	70	36.95	10.6	63.25	ND	14.1	47.15	15.4	35.55	4	Non-chronic	ND
Ulu []³³	European	57	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	ND	ND
Turgut []³⁴	European	162	63	52	100	65.5	ND	6.5	23.5	18	16.5	4	chronic	41.5
Jaremo (healthy control) []³⁵	European	82	67.5	66.7	ND	ND	ND	ND	ND	ND	ND	4	ND	2.55
jaremo (disease control) []³⁵	European	130	71.5	68.1	12.75	43.75	9.1	28.65	26.25	25.05	55.9	4	ND	9.45
Berge []³⁶	European	189	75	71	8	48	ND	19	21	34.5	28	4	ND	ND
Ertas (without stroke) []³⁷	European	111	53.5	51	ND	ND	ND	ND	ND	ND	ND	6	ND	2
Ertas (with stroke) []³⁷	European	63	54.5	47	ND	ND	ND	ND	ND	ND	ND	6	ND	5
Sahin []³⁸	European	144	64.9	49.75	100	66.5	ND	ND	ND	ND	ND	5	Non-chronic	44.5
Tekin []³⁹	European	219	73.5	35.5	13.5	68.5	ND	ND	ND	ND	ND	5	chronic	19
Turfan (without CVA) []⁴⁰	European	135	59.5	54.55	ND	ND	ND	ND	ND	ND	ND	4	ND	55.5
Turfan (with CVA) []⁴⁰	European	121	62.5	52.05	ND	ND	ND	ND	ND	ND	ND	4	ND	50.6
Feng []⁴¹	Asian	374	65.8	61.75	17.65	53.2	ND	23	41.95	44.85	42.5	4	ND	25.65
Acevedo []⁴²	South American	150	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	Non-chronic	ND
Hayashi []⁴³	Asian	27	57.95	92.5	14.5	48.5	ND	ND	40.5	26	ND	2	Non-chronic	ND
Hayashi []⁴³	Asian	27	61.45	92.5	11.05	52	ND	ND	37	26	ND	2	chronic	ND
Fu []⁴⁴	Asian	169	54.45	63.5	ND	ND	ND	ND	ND	12.9	6.1	4	ND	42.45
Hou (disease control) []⁴⁵	Asian	52	64.85	57.6	ND	ND	ND	ND	40.3	ND	11.45	4	Non-chronic	26.9
Hou (healthy control) []⁴⁵	Asian	52	65.3	57.6	ND	ND	ND	ND	21.15	ND	7.65	4	Non-chronic	26.9
Alberti []⁴⁶	European	51	64.45	58.8	ND	ND	ND	ND	ND	ND	ND	1	Non-chronic	ND
Choudhury (disease control) []⁴⁷	European	192	63.31	74	10.5	66.4	ND	33.15	55.7	46.5	43.7	4	ND	ND
Choudhury (healthy control) []⁴⁷	European	186	62.305	72	4.1	31.8	ND	17.75	26.85	14.45	21.9	4	ND	ND
Colkesen []⁴⁸	European	190	54	38	18.5	41.5	ND	ND	ND	28	ND	4	Non-chronic	ND
Blann []⁴⁹	European	82	64.5	62.75	ND	27	ND	16.5	19	ND	18.5	3	ND	12.6
Topaloglu (disease control) []⁵⁰	European	46	34.5	ND	ND	ND	ND	ND	ND	ND	ND	5	ND	ND
Topaloglu (healthy control) []⁵⁰	European	38	36	ND	ND	ND	ND	ND	ND	ND	ND	5	ND	ND
Yip []⁵¹	Asian	82	65.75	63.05	ND	ND	ND	ND	ND	ND	ND	3	chronic	ND
Heeringa []⁵²	European	486	77.5	51	17.5	25	22.5	31.65	ND	ND	16.55	5	ND	20.9
Inoue (with comorbidities) []⁵³	Asian	251	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	ND	ND
Inoue (lone AF) []⁵³	Asian	106	ND	ND	ND	ND	ND	ND	ND	ND	ND	5	ND	ND
Conway []⁵⁴	European	147	68	62	7.5	26.5	ND	ND	ND	ND	ND	3	chronic	16
Conway []⁵⁵	European	74	67.5	70.23	12.95	37	1.85	ND	ND	ND	ND	5	Non-chronic	16.2
Atalar (paroxysmal AF) []⁵⁶	European	37	46	61.8	0	35.9	ND	ND	ND	ND	17.845	1	Non-chronic	ND
Atalar (permanent AF) []⁵⁶	European	47	49	63.8	0	35.9	ND	ND	ND	ND	17.845	1	chronic	ND
Kamath []⁵⁷	European	62	63.5	51.6	ND	ND	ND	ND	ND	ND	ND	1	Non-chronic	ND
Kamath []⁵⁷	European	124	66	52.65	ND	ND	ND	ND	ND	ND	ND	1	chronic	ND
Kamath []⁵⁸	European	58	63	48.235	6.85	24.1	ND	ND	ND	ND	ND	4	Non-chronic	5.15
Kamath []⁵⁸	European	116	65	52.25	5.15	30.45	ND	ND	ND	ND	ND	4	chronic	5.15
Kamath []⁵⁹	European	143	70	63.2	5.35	29.565	ND	ND	ND	ND	ND	1	ND	ND
Kamath []⁶⁰	European	57	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Li-Saw-Hee []⁶¹	European	43	64	77.3	2.15	10.85	ND	ND	ND	ND	ND	3	Non-chronic	13.65
Li-Saw-Hee []⁶¹	European	43	64	77.3	2.15	13	ND	ND	ND	ND	ND	3	Non-chronic	11.52
Li-Saw-Hee []⁶¹	European	43	65	77.3	6.52	23.9	ND	ND	ND	ND	ND	3	chronic	11.52
Mondillo []⁶²	European	80	66.95	82.85	ND	ND	ND	ND	ND	ND	ND	3	chronic	33.75
Li-Saw-Hee []⁶³	European	112	67	77.5	3.85	12.5	ND	ND	ND	ND	ND	1	ND	13.3
Li-Saw-Hee []⁶⁴	European	50	59	20	ND	ND	ND	ND	ND	ND	ND	5	chronic	20
Minamino []⁶⁵	European	56	64	71.4	21.5	25	ND	ND	ND	ND	19.5	4	chronic	37.5
Minamino []⁶⁶	Asian	90	63	73.3	12.5	23.5	ND	ND	ND	ND	14.5	5	chronic	39
Kahn []⁶⁷	North American	81	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Sohara []⁶⁸	Asian	30	59.05	ND	ND	ND	ND	ND	ND	ND	ND	1	Non-chronic	ND
Lip GY []⁶⁹	European	77	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	chronic	ND
Nagao []⁷⁰	Asian	36	79.95	47.05	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Sohara []⁷¹	Asian	28	ND	ND	ND	ND	ND	ND	ND	ND	ND	1	Non-chronic	ND
Gustafsson (with stroke) []⁷²	European	60	77	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Gustafsson (without stroke) []⁷²	European	60	77	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Yamauchi (without valvular heart disease) []⁷³	Asian	130	41.5	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND
Yamauchi (with valvular heart disease) []⁷³	Asian	83	45.5	ND	ND	ND	ND	ND	ND	ND	ND	1	ND	ND

Back to the Article

Platelets Cellular and Functional Characteristics in Patients with Atrial Fibrillation: A Comprehensive Meta-Analysis and Systematic Review

Your Privacy